CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
On Aug. 23, CVS Health (NYSE: CVS) announced that it's launching a new subsidiary focused on biosimilar drugs. That business, Cordavis, will start by seeking to commercialize a biosimilar to 's blockbuster Humira. That could mean trouble on the horizon for Viatris (NASDAQ: VTRS). As a generic medicine manufacturer, the last thing it needs is another powerful competitor looking to grab a share of the most lucrative markets.
Here's what you need to know about the situation and how it might affect your investing thesis for Viatris stock.
Humira (adalimumab) is one of the most successful drugs of all time, bringing in more than $21 billion in revenue for AbbVie in 2022 even as multiple biosimilars of it hit the market in the E.U. and U.S.
Source Fool.com
AbbVie Inc. Aktie
Überwältigende Zustimmung für AbbVie Inc. mit ausschließlich Buy-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für AbbVie Inc. mit einem Kursziel von 180 € im Vergleich zum aktuellen Kurs von 169.8 €.
